Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00621244 · OUTCOME

Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies · Source last updated 2021-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentages of participants
Interval / dispersion
Not reported
Time frame
Days 1, 5, 8, 10, 15

What was measured

Reporting the number of patients with a reading at the timepoint in the dose group.

Analysis population: Full Analysis Set N=number of participants analyzed. total n=number of patients with a reading at the timepoint in the dose group.

Groups in this outcome

Arm 1, Group X (20 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.

Arm 1, Group X (30 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.

Arm 1, Group X (40 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.

Arm 1, Group X (60 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.

Arm 1, Group X (80 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 1, Group X (20 mg)8
Arm 1, Group X (30 mg)8
Arm 1, Group X (40 mg)10
Arm 1, Group X (60 mg)49
Arm 1, Group X (80 mg)11

Reported measurements

Day 1 (total=0, 1, 0, 0, 0)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group X (20 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (30 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (40 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (60 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (80 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Day 5 (total = 6, 4, 8, 17, 8)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group X (20 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (30 mg)75.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (40 mg)87.5Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (60 mg)82.4Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (80 mg)37.5Not reportedNot reportedNot reportedNot reported
Day 8 (total = 5, 4, 8, 17, 7)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group X (20 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (30 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (40 mg)75.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (60 mg)82.4Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (80 mg)57.1Not reportedNot reportedNot reportedNot reported
Day 10 (total=0, 0, 0, 0, 0, 1)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group X (20 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (30 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (40 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (60 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 1, Group X (80 mg)100.0Not reportedNot reportedNot reportedNot reported
Day 15 (total=3, 3, 4, 2, 2)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 1, Group X (20 mg)66.7Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (30 mg)33.3Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (40 mg)50.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (60 mg)50.0Not reportedNot reportedNot reportedNot reported
Arm 1, Group X (80 mg)50.0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        No patients were analyzed for this arm.
        group Id
        OG000
        value
        NA
      2. group Id
        OG001
        value
        100.0
      3. comment
        No patients were analyzed for this arm.
        group Id
        OG002
        value
        NA
      4. comment
        No patients were analyzed for this arm.
        group Id
        OG003
        value
        NA
      5. comment
        No patients were analyzed for this arm.
        group Id
        OG004
        value
        NA
    title
    Day 1 (total=0, 1, 0, 0, 0)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        100.0
      2. group Id
        OG001
        value
        75.0
      3. group Id
        OG002
        value
        87.5
      4. group Id
        OG003
        value
        82.4
      5. group Id
        OG004
        value
        37.5
    title
    Day 5 (total = 6, 4, 8, 17, 8)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        100.0
      2. group Id
        OG001
        value
        100.0
      3. group Id
        OG002
        value
        75.0
      4. group Id
        OG003
        value
        82.4
      5. group Id
        OG004
        value
        57.1
    title
    Day 8 (total = 5, 4, 8, 17, 7)
  4. categories
    1. measurements
      1. comment
        No patients were analyzed for this arm.
        group Id
        OG000
        value
        NA
      2. comment
        No patients were analyzed for this arm.
        group Id
        OG001
        value
        NA
      3. comment
        No patients were analyzed for this arm.
        group Id
        OG002
        value
        NA
      4. comment
        No patients were analyzed for this arm.
        group Id
        OG003
        value
        NA
      5. group Id
        OG004
        value
        100.0
    title
    Day 10 (total=0, 0, 0, 0, 0, 1)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        66.7
      2. group Id
        OG001
        value
        33.3
      3. group Id
        OG002
        value
        50.0
      4. group Id
        OG003
        value
        50.0
      5. group Id
        OG004
        value
        50.0
    title
    Day 15 (total=3, 3, 4, 2, 2)
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    2. group Id
      OG001
      value
      8
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      49
    5. group Id
      OG004
      value
      11
    units
    Participants
description
Reporting the number of patients with a reading at the timepoint in the dose group.
groups
  1. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.
    id
    OG000
    title
    Arm 1, Group X (20 mg)
  2. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.
    id
    OG001
    title
    Arm 1, Group X (30 mg)
  3. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.
    id
    OG002
    title
    Arm 1, Group X (40 mg)
  4. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.
    id
    OG003
    title
    Arm 1, Group X (60 mg)
  5. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.
    id
    OG004
    title
    Arm 1, Group X (80 mg)
param Type
NUMBER
population Description
Full Analysis Set N=number of participants analyzed. total n=number of patients with a reading at the timepoint in the dose group.
reporting Status
POSTED
time Frame
Days 1, 5, 8, 10, 15
title
Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X
type
SECONDARY
unit Of Measure
Percentages of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice